FAQs About Dupixent Lawsuits and T-Cell Lymphoma Risks

FAQs About Dupixent Lawsuits and T-Cell Lymphoma Risks

Thousands of patients prescribed Dupixent to treat eczema, asthma, or chronic sinusitis are now asking critical questions about its safety. Reports linking the drug to T-cell lymphoma and other forms of cancer have led to growing legal action. If you or someone you love developed cancer after taking Dupixent, understanding your legal rights and the status of Dupixent lawsuits is essential.

This comprehensive FAQ answers the most important questions about Dupixent-related cancer risks, ongoing lawsuits, and what you should do next if you’ve been affected.

1. Why Are People Filing Dupixent Lawsuits?

Dupixent lawsuits are being filed because patients claim the manufacturer, Regeneron Pharmaceuticals and Sanofi, failed to warn consumers and doctors about the drug’s potential to cause T-cell lymphoma and other immune-related cancers. These cases argue that the company either knew or should have known about these risks during clinical trials but continued to market the drug as safe for long-term use.

Plaintiffs in Dupixent lawsuits report developing severe medical conditions after treatment, including:

• T-cell lymphoma
• Cutaneous lymphoma (skin lymphoma)
• Other immune system cancers
• Chronic immune suppression

These claims allege not only inadequate safety testing but also aggressive marketing practices that downplayed potential cancer risks associated with Dupixent’s mechanism of action on the immune system.

2. What Is the Link Between Dupixent and T-Cell Lymphoma?

Dupixent (dupilumab) works by blocking specific proteins involved in the body’s immune response-IL-4 and IL-13. While this mechanism helps control inflammation in conditions like eczema, it can also interfere with immune surveillance, potentially allowing abnormal T-cells to proliferate unchecked. This process may increase the risk of developing certain lymphomas, particularly cutaneous T-cell lymphoma (CTCL).

In multiple case reports, patients developed CTCL within months of starting Dupixent therapy. Some of these cancers were initially misdiagnosed as worsening eczema-delaying proper treatment and allowing the cancer to spread. Researchers are still studying whether Dupixent directly triggers lymphoma or accelerates existing precancerous conditions, but the pattern is concerning enough that lawsuits are moving forward nationwide.

3. Who Qualifies to File a Dupixent Lawsuit?

You may qualify to file a Dupixent injury claim if you were prescribed Dupixent and later diagnosed with T-cell lymphoma or another immune-related cancer. Generally, claimants must meet the following criteria:

• Used Dupixent as prescribed for eczema, asthma, or chronic sinusitis
• Later developed T-cell lymphoma, cutaneous lymphoma, or another immune cancer
• Have medical records linking Dupixent use to cancer onset
• Were not warned about potential cancer risks

Family members may also bring a wrongful death claim if a loved one passed away from cancer believed to be caused by Dupixent. The best way to determine eligibility is to discuss your situation with our lawyers at Alonso Krangle, LLP, who can review your medical records and advise you on possible legal options.

4. Is There a Dupixent Class Action Lawsuit?

As of now, most Dupixent lawsuits are being filed as individual product liability cases rather than a single class action. This is common in pharmaceutical injury litigation, as cancer and injury claims vary greatly in severity, timeline, and damages. However, these cases may eventually be consolidated into a multidistrict litigation (MDL) to streamline pretrial proceedings and evidence discovery.

In an MDL, each plaintiff maintains their own case and potential compensation, but legal proceedings share a unified strategy for efficiency. This allows patients across the country to present consistent evidence about Dupixent’s risks while keeping their individual right to compensation intact.

If a class action or MDL is officially formed, our firm will be closely involved in representing patients and ensuring victims’ voices are heard in this nationwide litigation.

5. What Compensation Can Dupixent Victims Seek?

Victims of Dupixent-related cancer may seek compensation for both economic and non-economic losses. Lawsuits typically demand payment for the following damages:

• Medical expenses for diagnosis, treatment, and ongoing care
• Lost wages or diminished earning capacity
• Pain and suffering related to the cancer diagnosis
• Emotional distress and anxiety
• Loss of quality of life
• Wrongful death damages (for surviving family members)

Courts may also award punitive damages if evidence shows the manufacturers acted recklessly or concealed critical safety information. These awards aim to hold corporations accountable and deter similar misconduct in the future.

6. What Should You Do If You Developed Cancer After Taking Dupixent?

If you were diagnosed with T-cell lymphoma or another immune-related cancer after taking Dupixent, taking the right steps now is critical to protect your health and legal rights. Here’s what to do:

• Stop taking Dupixent only under medical supervision
• Obtain copies of your medical records, including biopsy results
• Document your Dupixent prescription history
• Contact our firm promptly to begin your claim investigation

Timing is crucial. Each state has its own statute of limitations that restricts how long you have to file a claim. Even if your diagnosis occurred months or years ago, it’s worth consulting with our team to explore your options before the filing window closes.

7. Are There Warnings About Dupixent’s Cancer Risks?

Currently, the FDA-approved labeling for Dupixent does not include an explicit warning about T-cell lymphoma. However, emerging medical literature and post-marketing reports have increasingly linked the drug to cutaneous lymphomas. Many experts are now urging the FDA to require stronger warnings and further safety studies.

Patients allege that if Regeneron and Sanofi had properly disclosed these risks, they could have made informed decisions about their treatment options or chosen safer alternatives. Failure to provide such warnings is one of the central claims in ongoing Dupixent lawsuits.

8. How Can Our Firm Help With Your Dupixent Lawsuit?

Our attorneys at Alonso Krangle, LLP are investigating Dupixent cancer claims on behalf of patients across the country. We help gather medical evidence, connect with expert witnesses, and pursue maximum compensation for your injuries. If you or a loved one developed T-cell lymphoma or another cancer after taking Dupixent, we encourage you to contact us as soon as possible to discuss your potential case.

Call [PHONE] or complete our online form for a free, confidential consultation. Our firm is committed to standing up to pharmaceutical corporations and holding them accountable for the harm caused by dangerous medications.